Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy

Journal of the Neurological Sciences

Volumn 292, Issue 1-2, 2010, Pages 63-71

  Boërio, Delphine ^a,b,c   Créange, Alain ^a,b   Hogrel, Jean Yves ^c   Guéguen, Antoine ^a,b   Bertrand, Dominique ^d   Lefaucheur, Jean Pascal ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ONIRIS   (France)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Conduction block; Intravenous immunoglobulin; Multifocal motor neuropathy; Rheobase; Sodium conductance; Strength duration time constant; Supernormality

Indexed keywords

IMMUNOGLOBULIN; SODIUM ION;

ADULT; AGED; ARTICLE; CHRONAXY; CHRONIC DISEASE; DEMYELINATING NEUROPATHY; DRUG EFFICACY; DRUG INFUSION; FEMALE; HUMAN; MALE; MOTOR NEUROPATHY; NERVE CELL EXCITABILITY; NERVE EXCITABILITY; NERVE FIBER REGENERATION; NEUROPROTECTION; PRIORITY JOURNAL; REFRACTORY PERIOD; REMYELINIZATION; SODIUM TRANSPORT; STIMULUS RESPONSE; TIME; ULNAR NERVE;

ADULT; AGED; AGED, 80 AND OVER; DEMYELINATING DISEASES; ELECTROMYOGRAPHY; FEMALE; HAND STRENGTH; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEURONS, AFFERENT; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SODIUM CHANNELS; TREATMENT OUTCOME; ULNAR NERVE;

EID: 77950070266     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.02.002     Document Type: Article

References (43)

1. Hughes R.A., Bouche P., Cornblath D.R., Evers E., Hadden R.D., Hahn A., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 13 (2006) 326-332
2. van Schaik I.N., Bouche P., Illa I., Léger J.M., Van den Bergh P., Cornblath D.R., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 13 (2006) 802-808
3. Hahn A.F., Bolton C.F., Zochodne D., and Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119 (1996) 1067-1077
4. Mendell J.R., Barohn R.J., Freimer M.L., Kissel J.T., King W., Nagaraja H.N., et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56 (2001) 445-449
5. Vermeulen M., van Doorn P.A., Brand A., Strengers P.F., Jennekens F.G., and Busch H.F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56 (1993) 36-39
6. Chaudhry V., Corse A.M., Cornblath D.R., Kuncl R.W., Drachman D.B., Freimer M.L., et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 33 (1993) 237-242
7. Kaji R., Shibasaki H., and Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 42 (1992) 506-509
8. Nobile-Orazio E., Meucci N., Barbieri S., Carpo M., and Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43 (1993) 537-544
9. Léger J.M., Chassande B., Musset L., Meininger V., Bouche P., and Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124 (2001) 145-153
10. Van den Berg L.H., Kerkhoff H., Oey P.L., Franssen H., Mollee I., Vermeulen M., et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59 (1995) 248-252
11. Van den Berg L.H., Franssen H., and Wokke J.H. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 121 (1998) 421-428
12. Créange A., Gregson N.A., and Hughes R.A. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol 135 (2003) 91-95
13. Dalakas M. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59 (2002) 13-21
14. Kazatchkine M., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
15. Bostock H., Cikurel K., and Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21 (1998) 137-158
16. Kiernan M.C., Burke D., Andersen K.V., and Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 23 (2000) 399-409
17. Krishnan A.V., Lin C.S., Park S.B., and Kiernan M.C. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst 13 (2008) 7-26
18. Lefaucheur J.P., Boërio D., Hogrel J.Y., and Créange A. Etude de l'excitabilité nerveuse dans l'exploration des neuropathies dysimmunitaires. Rev Neurol (Paris) 162 (2006) 3S19-28
19. Kiernan M.C., Guglielmi J.M., Kaji R., Murray N.M., and Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 125 (2002) 664-675
20. Priori A., Cinnante C., Pesenti A., Carpo M., Cappellari A., Nobile-Orazio E., et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain 125 (2002) 2481-2490
21. Kleyweg R.P., van der Meché F.G.A., and Schmitz P.I.M. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14 (1991) 1103-1109
22. Ingram D.A., Davis G.R., and Swash M. The double collision technique: a new method for measurement of the motor nerve refractory period distribution in man. Electroencephalogr Clin Neurophysiol 66 (1987) 225-234
23. Boërio D., Hogrel J.Y., Créange A., and Lefaucheur J.P. A reappraisal of various methods for measuring motor nerve refractory period in humans. Clin Neurophysiol 116 (2005) 969-976
24. Kiernan M.C., Mogyoros I., and Burke D. Differences in the recovery of excitability in sensory and motor axons of human median nerve. Brain 119 (1996) 1099-1105
25. Brismar T. Changes in electrical threshold in human peripheral neuropathy. J Neurol Sci 68 (1985) 215-223
26. Bostock H., and Bergmans J. Post-tetanic excitability changes and ectopic discharges in a human motor axon. Brain 117 (1994) 913-928
27. Cappelen-Smith C., Kuwabara S., Lin C.S., Mogyoros I., and Burke D. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 48 (2000) 826-832
28. Cappelen-Smith C., Kuwabara S., Lin C.S., and Burke D. Abnormalities of axonal excitability are not generalized in early multifocal motor neuropathy. Muscle Nerve 26 (2002) 769-776
29. Cappelen-Smith C., Kuwabara S., Lin C.S., Mogyoros I., and Burke D. Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 124 (2001) 2439-2447
30. Cappelen-Smith C., Lin C.S., Kuwabara S., and Burke D. Conduction block during and after ischaemia in chronic inflammatory demyelinating polyneuropathy. Brain 125 (2002) 1850-1858
31. Bostock H., and Rothwell J.C. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol (London) 498 (1997) 277-294
32. Mogyoros I., Kiernan M.C., and Burke D. Strength-duration properties of human peripheral nerve. Brain 119 (1996) 439-447
33. Craner M.J., Newcombe J., Black J.A., Hartle C., Cuzner M.L., and Waxman S.G. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 101 (2004) 8168-8173
34. Bechtold D.A., and Smith K.J. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 233 (2005) 27-35
35. Stys P.K., and Waxman S.G. Activity-dependent modulation of excitability: implication for axonal physiology and physiolpathology. Muscle Nerve 17 (1994) 969-974
36. Vucic S., Black K.R., Chong P.S., and Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63 (2004) 1264-1269
37. Vucic S., Black K., Baldassari L.E., Tick Chong P.S., Dawson K.T., and Cros D. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol 118 (2007) 1980-1984
38. Misawa S., Kuwabara S., Kanai K., Tamura N., Nakata M., Ogawara K., et al. Nodal persistent Na+ currents in human diabetic nerves estimated by the technique of latent addition. Clin Neurophysiol 117 (2006) 815-820
39. Tamura N., Kuwabara S., Misawa S., Kanai K., Nakata M., Sawai S., et al. Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol 117 (2006) 2451-2458
40. Boërio D., Hogrel J.Y., Lefaucheur J.P., Wang F.C., Verschueren A., Pouget J., et al. Stimulus-response curve of human motor nerves: multicenter assessment of various indexes. Neurophysiol Clin 38 (2008) 31-38
41. Mogyoros I., Lin C., Dowla S., Grosskreutz J., and Burke D. Reproducibility of indices of axonal excitability in human subjects. Clin Neurophysiol 111 (2000) 23-28
42. Ghosh A., Virgincar A., Kennett R., Busby M., and Donaghy M. The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 76 (2005) 1269-1272
43. Van Doorn P.A., Vermeulen M., Brand A., Mulder P.G., and Busch H.F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48 (1991) 217-220